

## MolecuLighting up!



The MolecuLight is a point of care technology that uses bacterial fluorescence imaging to help nursing and medical team members identify bacterial contamination and has facilitated targeted intervention including wound swabs and debridement<sup>2</sup>. Novosorb™ Biodegradable Temporing Matrix (BTM) is a fully synthetic dermal scaffold for tissue repair, and contributes to stable, durable and flexible wound closure<sup>3</sup>.



On presentation    Post debridement    Post QV wash    Post gentamicin wash    Intraoperative debridement

## BTM and the MolecuLight in the management of chronic ulceration in ataxia telangiectasia. [Dr Alicia Miers](#), Kristen Storey, Professor Roy Kimble



Ataxia telangiectasia is a neurocutaneous syndrome characterised by faulty DNA damage repair. Cutaneous granulomas are an uncommon feature and require long term wound management in parallel with systemic immunotherapy<sup>1</sup>. This is a case report of the recent use of the MolecuLight and Biodegradable Temporing Matrix (BTM) in the management of lower limb ulcerating granulomatous skin changes complicated by pseudomonas infection in a 15 year old with ataxia telangiectasia. Prior to the utilisation of these technologies, options including limb amputation had been considered.

Management of this patient's granulomatous lesions over the last 12 months has included; twice weekly dressings, steroid injections, acetic acid washes, gentamicin washes, and most recently targeted cleaning and debridement with the help of the MolecuLight followed by operative debridement and application of BTM. This patient was not suitable for skin grafting, however BTM was applied on 2 occasions with significant reduction of the size of large ulcers and re-epithelialisation of smaller ulcers.

Together, these technologies have transformed the wound care management for this patient, including the reduced requirement for analgesia, sedation or general anaesthetic. The wound care for this patient is ongoing and we hope to continue to share our local experience of the management of this rare paediatric condition.

### Reference List

1. Privette, ED, Ram, G, Treat, JR, Yan, AC & Heimall, JR 2014, 'Healing of Granulomatous Skin Changes in Ataxia-Telangiectasia After Treatment with Intravenous Immunoglobulin and Topical Mometasone 0.1% Ointment', *Pediatric Dermatology*, vol. 31, no. 6, pp. 703-7.
2. DaCosta, RS, Kulbatski, I, Lindvere-Teene, L, Starr, D, Blackmore, K, Silver, JJ, Opoku, J, Wu, YC, Medeiros, PJ, Xu, W, Xu, L, Wilson, BC, Rosen, C & Linden, R 2015, 'Point-of-Care Autofluorescence Imaging for Real-Time Sampling and Treatment Guidance of Bioburden in Chronic Wounds: First-in-Human Results', *PLoS ONE*, vol. 10, no. 3.
3. Cheshire, PA, Herson, MR, Cleland, H & Akbarzadeh, S 2016, Artificial dermal templates: A comparative study of NovoSorb™ Biodegradable Temporing Matrix (BTM) and Integra® Dermal Regeneration Template (DRT), 03054179.



Debridement under anaesthetic



Application of BTM (Day 0)



Day 33 post application of BTM